Comparison · NCT05171647-sae
Arm A: Mosun-Pola vs Arm B: R-GemOx: serious adverse events
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
2 sourcestrial-comparisons-2026-03-23-0.1.0
Cite this record
ConductScience Library. Arm A: Mosun-Pola vs Arm B: R-GemOx: serious adverse events. Trial comparisons, record NCT05171647-sae. Release trial-comparisons-2026-03-23-0.1.0, 23 Mar 2026. https://conductscience.org/library/comparisons/NCT05171647-sae
On this page
Measures6
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
| Measure | Value | 95% interval, lower | 95% interval, upper | Method | Note |
|---|---|---|---|---|---|
| Risk in group 1 | 0.333 | 0.259 | 0.416 | wilson | |
| Risk in group 2 | 0.25 | 0.16 | 0.368 | wilson | |
| Risk difference, group 1 minus group 2 | 0.0833 | -0.0561 | 0.206 | newcombe hybrid score | |
| Risk ratio, group 1 over group 2 | 1.33 | 0.819 | 2.17 | log | |
| Odds ratio, group 1 over group 2 | 1.5 | 0.768 | 2.93 | log | |
| Number needed to harm, for one more participant with a serious adverse event on Arm A: Mosun-Pola than on Arm B: R-GemOx | 12 | from the risk difference interval | the interval includes no difference |
Source ClinicalTrials.gov
Groups2
Neither group, or both, names a comparator, so the groups keep ClinicalTrials.gov's order.
| Group | Title | Description | With the outcome | Analysed | ClinicalTrials.gov code |
|---|---|---|---|---|---|
| Group 1 | Arm A: Mosun-Pola | Participants received mosunetuzumab, 5 mg, SC, on Day 1 of Cycle 1, followed by 45 mg, SC, on Days 8 \& 15 of Cycle 1 and thereafter on Day 1 of Cycles 2 to 8, in combination with polatuzumab vedotin, 1.8 mg/kg, IV, on Day 1 of Cycles 1 to 6 (1 Cycle=21 days). | 45 | 135 | EG000 |
| Group 2 | Arm B: R-GemOx | Participants received rituximab, 375 milligrams per square meter (mg/m\^2), IV, in combination with gemcitabine, 1000 mg/m\^2, and oxaliplatin, 100 mg/m\^2, IV, on Day 1 of Cycles 1 to 8 (1 Cycle=14-21 days). | 16 | 64 | EG001 |
Source ClinicalTrials.gov
Harm
- What it counts
- Total, serious adverse events
- Time frame
- From initiation of study drug up to approximately 33.7 months
Source ClinicalTrials.gov
Trial
- Title
A Study Evaluating Efficacy and Safety of Mosunetuzumab in Combination With Polatuzumab Vedotin Compared to Rituximab in Combination With Gemcitabine Plus Oxaliplatin in Participants With Relapsed or Refractory Aggressive B-Cell Non-Hodgkin's Lymphoma
- NCT number
- NCT05171647
- Phases
- PHASE3
- Conditions
- Non-Hodgkin Lymphoma
- Interventions
- Mosunetuzumab, Polatuzumab vedotin, Tocilizumab, Rituximab, Gemcitabine, Oxaliplatin
- Lead sponsor
- Hoffmann-La Roche
- Results first posted
- 2026-03-06
- Results on ClinicalTrials.gov
- https://clinicaltrials.gov/study/NCT05171647?tab=results
Source ClinicalTrials.gov
Source
- Release
- trial-comparisons-2026-03-23-0.1.0
- Release manifest SHA-256
- f66225897fbf258b57ea10bdacfd0347d3cdfda93f7f5685234b7e06ea36fa57
- AACT copy
- 2026-03-23
- Tables read
- outcome_counts.parquet, outcome_measurements.parquet, outcomes.parquet, reported_event_totals.parquet, reported_events.parquet, result_groups.parquet, studies.parquet, ctgov_trial.parquet
Source ClinicalTrials.gov
Sources 2
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.
For software
Read this comparison from software.
The record is JSON. No key.
GET https://conductscience.org/api/comparisons/v1/NCT05171647-sae